ProQR Therapeutics N.V
ProQR Therapeutics N.V (PRQR) Implied Volatility Current
PRQR implied volatility is 314%. IV Rank is 54%, placing current premiums in the middle of their 52-week range.
Read more
Tracking PRQR implied volatility helps you identify when options premiums on ProQR Therapeutics N.V are historically cheap or expensive, and where the best trades are hiding. ProQR Therapeutics N.V implied volatility reflects the market's expectation of future price movement: when PRQR IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor ProQR Therapeutics N.V's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For PRQR, tracking metrics like PRQR IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on PRQR signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where PRQR implied volatility sits today versus where it has been. Our scanner ranks ProQR Therapeutics N.V implied volatility against its historical range, surfaces extremes in PRQR IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether ProQR Therapeutics N.V IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is slightly elevated - premiums are richer, leaning toward sellers.
As of September 25, 2026
Trade options with IV on your side
Track PRQR IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→